Yatagarasu: A single-arm, open-label, phase 2 study of apalutamide (APA) plus goserelin (GOS) for patients (pts) with far locally advanced or recurrent/metastatic (fLA/RM) and androgen receptor (AR)-expressing salivary gland carcinoma (SGC).
Yatagarasu: A single-arm, open-label, phase 2 study of apalutamide (APA) plus goserelin (GOS) for patients (pts) with far locally advanced or recurrent/metastatic (fLA/RM) and androgen receptor (AR)-expressing salivary gland carcinoma (SGC).
复制标题
Yatagarasu：阿帕鲁胺 (APA) 加戈舍瑞林 (GOS) 治疗局部晚期或复发/转移性 (fLA/RM) 且表达雄激素受体 (AR) 的患者 (pts) 的单臂、开放标签 2 期研究
DOI：
--
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Sunee
中科院分区：
文献类型：
--
作者：
Yoshitaka Honma;Nobuya Monden;Keisuke Yamazaki;Satoshi Kano;Hironaga Satake;Shigenori Kadowaki;Toshitaka Nagao;Tomohiko Nakatogawa;Koji Fujii;Yosuke Koroki;Junya Aoyama;Shohei Ouchi;Tetsuro Ogawa;Sharon McCarthy;Sabine D. Brookman-May;Sunee
